Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price increased by UBS Group from $615.00 to $640.00 in a research report released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the pharmaceutical company’s stock.
A number of other analysts also recently issued reports on VRTX. Barclays raised their price objective on shares of Vertex Pharmaceuticals from $615.00 to $617.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Truist Financial boosted their target price on shares of Vertex Pharmaceuticals from $560.00 to $565.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Wall Street Zen downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 31st. Daiwa Securities Group increased their target price on shares of Vertex Pharmaceuticals from $555.00 to $556.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Finally, Stifel Nicolaus raised their price target on shares of Vertex Pharmaceuticals from $500.00 to $563.00 and gave the stock a “hold” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $596.44.
Read Our Latest Stock Analysis on VRTX
Vertex Pharmaceuticals Trading Down 1.2%
Shares of Vertex Pharmaceuticals stock opened at $542.50 on Tuesday. The firm has a market cap of $137.69 billion, a PE ratio of 34.91, a P/E/G ratio of 2.84 and a beta of 0.28. Vertex Pharmaceuticals has a 1 year low of $406.67 and a 1 year high of $568.67. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.34 and a quick ratio of 2.74. The stock has a fifty day moving average price of $522.81 and a 200-day moving average price of $481.42.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). The company had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. Vertex Pharmaceuticals’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same period last year, the firm posted $4.80 earnings per share. Equities research analysts anticipate that Vertex Pharmaceuticals will post 16.50 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in Vertex Pharmaceuticals during the second quarter valued at about $11,975,849,000. State Street Corp increased its stake in shares of Vertex Pharmaceuticals by 1.2% in the second quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company’s stock worth $5,896,910,000 after purchasing an additional 141,320 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Vertex Pharmaceuticals by 1.1% in the second quarter. Wellington Management Group LLP now owns 3,247,658 shares of the pharmaceutical company’s stock worth $1,613,209,000 after purchasing an additional 35,069 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Vertex Pharmaceuticals by 1.0% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,086,683 shares of the pharmaceutical company’s stock worth $1,533,248,000 after purchasing an additional 29,287 shares in the last quarter. Finally, Bank of America Corp DE bought a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at approximately $1,509,651,000. Institutional investors own 90.96% of the company’s stock.
Key Vertex Pharmaceuticals News
Here are the key news stories impacting Vertex Pharmaceuticals this week:
- Positive Sentiment: Vertex reported third-quarter revenue of $3.44 billion, up about 12% year over year, and raised its 2026 revenue forecast to $13.15 billion–$13.25 billion. Growth was supported by its cystic fibrosis business and newer products, including CASGEVY. The company also faces a key November 30 FDA decision date for povetacicept in IgA nephropathy. Q3 earnings call highlights
- Positive Sentiment: Multiple analysts raised Vertex price targets or reiterated Buy/Overweight ratings, including Barclays, TD Cowen, JPMorgan, Goldman Sachs, Stifel, Cantor Fitzgerald, RBC, UBS, Wells Fargo, and Scotiabank. The broad positive analyst tone points to confidence in the company’s outlook. Barclays price-target increase
- Positive Sentiment: A longer-term bullish view cited Vertex’s strong position in cystic fibrosis and its gradual expansion into other treatments as reasons it could remain an attractive biotech stock. Long-term outlook
- Neutral Sentiment: Third-quarter revenue exceeded analyst estimates, but earnings per share of $4.76 came in slightly below the $4.82 consensus—an offset to the encouraging sales and guidance update.
- Negative Sentiment: Morgan Stanley lowered its expectations for Vertex’s stock price, offering a counterpoint to the wave of target increases. Morgan Stanley outlook
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.
Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.
Further Reading
- Five stocks we like better than Vertex Pharmaceuticals
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
